Microarray patch technology has the potential to foster untold gains in access, efficacy, and adherence for vaccines and essential medicines. PATH is working to accelerate the development of this innovative delivery technology platform to address critical public health needs. PATH is collaborating with microarray patch (MAP) developers, vaccine and drug manufacturers, and other global stakeholders to evaluate and advance a range of MAPs at varying stages of product development, with the aim of improving access and equity in the delivery of vaccines and essential medicines in resource constrained settings.